Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab vedotin versus docetaxel in previously treated c-Met overexpressing EGFR wildtype non-squamous NSCLC
NL-OMON59691Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of telisotuzumab vedotin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Progression-Free Survival and Overall Survival. Started May 2022; status: recruiting.
02
Drugs
telisotuzumab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59691.